The database indicates only one possible death of a recipient of the Johnson & Johnson shot from Guillain-Barré syndrome.
Even though it requires only one dose and is easier to store than Pfizer’s and Moderna’s vaccines, Johnson & Johnson’s shot has played only a minor role in the U.S. inoculation campaign.
At that time, 15 women in the United States and Europe who had received the Johnson & Johnson shot were diagnosed with the clotting disorder; three died.
Alex Gorsky, Johnson & Johnson’s chief executive, said last month that he was still hopeful that the vaccine, which has been used in 27 countries, would help contain the pandemic overseas.
Studies have showed that the Johnson & Johnson shot protects people against more contagious coronavirus variants, including the Delta variant, and is highly effective at preventing severe Covid-19, hospitalizations and death.
Johnson, Alex Gorsky
Emergent, African Union, Drug Administration
Delaware, U.S, Baltimore, United States, Europe